Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nab-paclitaxel and Trastuzumab for ER- HER2+ Breast Cancer
NCT02598310Phase 2Terminated
- Sponsor
- Osaka Medical and Pharmaceutical University
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel in breast cancer, sponsored by Osaka Medical and Pharmaceutical University. Started Nov 2015; status: terminated.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02598310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598310.